Literature DB >> 15681808

Melatonin relieves the neural oxidative burden that contributes to dementias.

Russel J Reiter1, Dun-Xian Tan, Miguel A Pappolla.   

Abstract

This report summarizes some of the many publications that document the beneficial actions of melatonin within the central nervous system. Of particular interest are the multiple functions of melatonin and its metabolites as ubiquitously acting direct free radical scavengers and indirect antioxidants. The fact that melatonin and the metabolic progeny that are formed when it scavenges toxic reactants are all effective in neutralizing destructive molecules greatly increases the efficacy of melatonin as a protection against by-products of oxygen and nitrogen that normally mutilate essential molecules. Of the large number of situations in which oxidative stress may be the cause of disease processes or debilitating conditions, the current review examines melatonin's protection within the central nervous system, particularly in experimental ischemia/reperfusion (stroke) injury, Alzheimer's disease, and parkinsonism. In each of these conditions, melatonin has been found to provide significant neural protection against both the morphophysiological damage and the biobehavioral consequences of these infirmities. The report concludes with the suggestion that melatonin, alone or in combination with other antioxidants, be considered for routine usage to potentially combat some of the neural ravages of aging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15681808     DOI: 10.1196/annals.1332.012

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  17 in total

Review 1.  Melatonin and Parkinson's disease.

Authors:  Juan C Mayo; Rosa M Sainz; Dun-Xian Tan; Isaac Antolín; Carmen Rodríguez; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 2.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  Melatonin protects N2a against ischemia/reperfusion injury through autophagy enhancement.

Authors:  Yanchun Guo; Jianfei Wang; Zhongqiang Wang; Yi Yang; Ximing Wang; Qiuhong Duan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-02-14

4.  Development of the new group of indole-derived neuroprotective drugs affecting oxidative stress.

Authors:  S Stolc; V Snirc; M Májeková; Z Gáspárová; A Gajdosíková; S Stvrtina
Journal:  Cell Mol Neurobiol       Date:  2006-05-17       Impact factor: 5.046

5.  Violet and blue light blocking intraocular lenses: photoprotection versus photoreception.

Authors:  M A Mainster
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

6.  The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors.

Authors:  Arabinda Das; Misty McDowell; Matthew J Pava; Joshua A Smith; Russel J Reiter; John J Woodward; Abhay K Varma; Swapan K Ray; Naren L Banik
Journal:  J Pineal Res       Date:  2010-01-17       Impact factor: 13.007

7.  Drug- and region-specific effects of protracted antidepressant and cocaine treatment on the content of melatonin MT(1) and MT(2) receptor mRNA in the mouse brain.

Authors:  Marta Imbesi; Tolga Uz; Sevim Yildiz; Ahmet D Arslan; Hari Manev
Journal:  Int J Neuroprot Neuroregener       Date:  2006

Review 8.  Role of melatonin in metabolic regulation.

Authors:  Ahmet Korkmaz; Turgut Topal; Dun-Xian Tan; Russel J Reiter
Journal:  Rev Endocr Metab Disord       Date:  2009-12       Impact factor: 6.514

9.  Melatonin: a novel indolamine in oral health and disease.

Authors:  V K Chava; K Sirisha
Journal:  Int J Dent       Date:  2012-07-31

10.  Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders.

Authors:  Genaro G Ortiz; Gloria A Benítez-King; Sergio A Rosales-Corral; Fermín P Pacheco-Moisés; Irma E Velázquez-Brizuela
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.